Anetumab ravtansine

Drug Profile

Anetumab ravtansine

Alternative Names: Anti-mesothelin antibody-drug conjugate BAY 94-9343; Anti-mesothelin-ADC-BAY-94-9343; BAY-94-9343; BAY-94-9343-SPDB-DM4

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; ImmunoGen; MorphoSys; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Mesothelioma; Pancreatic cancer; Solid tumours
  • Phase I Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 06 Mar 2018 Mayo Clinic in collaboration with National Cancer Institute, plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT03455556)
  • 26 Oct 2017 Interim efficacy and adverse events data from phase Ib trial in Mesothelioma and Non-small cell lung cancer was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC - 2017)
  • 04 Jul 2017 Bayer completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan (IV) (NCT02485119)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top